This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (24)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Academic Medical Centers  • Conflict of Interest  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Promoting Research While Maintaining Trust

Michael M. E. Johns, MD; Mark Barnes, JD, LLM; Patrik S. Florencio, LLB, BCL

JAMA. 2003;289:741-746.

Economic partnerships between industry and academia accelerate medical innovation and enhance patient access to medical advances, but such partnerships have sometimes eroded public trust in the research enterprise. There is particular risk for conflict of interest when economic partnerships extend beyond a university's corporate interests to involve institutional decision makers. Institutions and institutional decision makers should fully disclose industry-related financial interests and relationships. Without legitimate justification for such interests, individuals should divest themselves from these interests or recuse themselves from responsibility for research oversight. Management of institutional partnerships also might entail the physical separation of certain facilities, the placement of restrictions on information shared between investment and research staffs, and provision of oversight by independent review panels made up of persons who have expertise in intellectual property, finance, and research, but who are not financially or otherwise dependent on the institution. Through these means, it is possible to restore balance to industry-academia relationships, thereby promoting progress while maintaining public trust in research.

Author Affiliations: Robert W. Woodruff Health Sciences Center, Emory University, Atlanta, Ga (Dr Johns); Health Care Group, Ropes & Gray, New York, NY (Mssrs Barnes and Florencio).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Handling Conflicts of Interest Between Industry and Academia
David S. Egilman and Lynn H. Ehrle
JAMA. 2003;289(24):3240.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Incremental Drug Treatment Cost in HIV-Positive Patients in Industry-Sponsored Clinical Trials
Perrin and Lopez
The Annals of Pharmacotherapy 2008;42:1586-1591.
ABSTRACT | FULL TEXT  

Invited Article: Conflicts of interest for authors of American Academy of Neurology clinical practice guidelines
Holloway et al.
Neurology 2008;71:57-63.
ABSTRACT | FULL TEXT  

Responses of Medical Schools to Institutional Conflicts of Interest
Ehringhaus et al.
JAMA 2008;299:665-671.
ABSTRACT | FULL TEXT  

Origin and funding of the most frequently cited papers in medicine: database analysis
Patsopoulos et al.
BMJ 2006;332:1061-1064.
ABSTRACT | FULL TEXT  

Principles and Process in the Development of the Mayo Clinic's Individual and Institutional Conflict of Interest Policy
Camilleri et al.
Mayo Clin Proc. 2005;80:1340-1346.
ABSTRACT  

Regulating Academic-Industrial Research Relationships -- Solving Problems or Stifling Progress?
Stossel
NEJM 2005;353:1060-1065.
FULL TEXT  

Industry Funding of Clinical Trials: Benefit or Bias?
Chopra
JAMA 2003;290:113-114.
FULL TEXT  

Handling Conflicts of Interest Between Industry and Academia
Egilman and Ehrle
JAMA 2003;289:3240-3240.
FULL TEXT  

The "Price" of Information
Heinig
J Hum Lact 2003;19:133-135.
 

The power of clinical trials and guidelines,and the challenge of conflicts of interest
Bruce Fye
J Am Coll Cardiol 2003;41:1237-1242.
FULL TEXT